477 Results
Sort By:
Published on November 5, 2024
New diagnostic criteria for Alzheimer’s disease (AD) were announced recently by the International Working Group (IWG) at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain. A significant change in these diagnostic recommendations, published in JAMA Neurology, is defining the disease as a clinical-biological entity where diagnosis takes…
Published on October 30, 2024
A Phase I/II study of Lexeo Therapeutics’ gene therapy to treat patients with Alzheimer’s associated with the APOE4 genetic variant has achieved good interim results according to the company. If approved, this therapy (currently known as LX1001) would be ground-breaking as the first gene therapy for Alzheimer’s disease in a…
Published on October 30, 2024
AbbVie is acquiring blood-brain technology pioneer Aliada Therapeutics for $1.4B, according to an announcement yesterday. Aliada’s lead candidate, ALIA-1758, is developed using its Modular Delivery (MODEL) technology. It’s an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody against Alzheimer’s disease. Alzheimer’s is a very competitive field right now. The global market is estimated…
Published on October 28, 2024
When compared to seven other anti-diabetic drugs, semaglutide may significantly lower the risk of Alzheimer’s disease in people with type 2 diabetes, according to new research from the Case Western Reserve School of Medicine. These results, which were based on data from a national health records database, were consistent across…
Published on October 10, 2024
Scientists at the University of Pittsburgh have validated a new blood test platform capable of simultaneously measuring more than one hundred biomarkers of Alzheimer’s disease (AD). This new diagnostic called the NULISAseq CNS Disease Panel 120 has the potential to alter the landscape of AD diagnostics by allowing physicians to…
Published on October 4, 2024
A study conducted by researchers at the Johns Hopkins University School of Medicine and Tufts University School of Medicine, shows that a synthetic THC, known as dronabinol, has been shown to effectively reduce agitation in Alzheimer’s disease (AD) patients. The findings, presented at the International Psychogeriatric Association conference in Buenos…
Published on October 3, 2024
An international team of researchers has developed a promising new drug that works on both major Tau protein aggregation “hotspots,” a key driver of neurodegeneration including Alzheimer’s disease. The novel peptide inhibitor, RI-AG03, has demonstrated efficacy in preventing Tau aggregation in both laboratory and fruit fly studies, while showing no…
Published on September 13, 2024
Researchers from the Medical Research Council Laboratory of Molecular Biology (MRC LMB) in Cambridge, England and the UK Dementia Research Institute (UK DRI) at the University of Cambridge have developed new potential therapies that selectively remove the aggregated tau tangles to treat Alzheimer’s disease (AD). Their work, detailed in two…
Published on September 11, 2024
A new study from researchers at the University of Cincinnati (UC) challenges the conventional view that newly approved monoclonal antibody Alzheimer’s drugs primarily work by clearing amyloid plaques. The research indicates that increases in a critical brain protein, rather than reductions in amyloid plaques, might be contributing to the slowing…
Published on September 5, 2024
Methods for the diagnosis of Alzheimer’s disease (AD) today typically rely on a combination of medical history, cognitive and neurological functioning assessments, as well as brain imaging a handful of molecular tests. Now, analytical geochemists at the University of Melbourne, Australia, say they developed a blood test to detect levels…
Published on August 26, 2024
A team of researchers at Sweden’s Karolinska Institutet says that a ten-year study has shown the potential benefits of drugs called cholinesterase inhibitors (ChEIs) as treatment for patients suffering from dementia with Lewy bodies. Lewy body disease includes both dementia with Lewy bodies (DLB) and Parkinson’s disease with and without…
Published on August 15, 2024
A recent meta-analysis conducted by researchers at the University of New South Wales in Australia has revealed that older adults with untreated high blood pressure are at a significantly higher risk of developing Alzheimer’s disease. The study, published in Neurology, found that people aged 60 and older with untreated hypertension…
Published on August 2, 2024
A novel technique developed by researchers at the Washington University (WashU) School of Medicine has allowed them to study aged neurons in the lab without the need for a brain biopsy. The technique has identified aspects of the genome of cells in the development of late-onset Alzheimer’s disease (AD) that…
Published on July 25, 2024
A research team led by the Broad Institute of MIT and Harvard has mapped gene expression across six areas of the brain linked to Alzheimer’s disease using a single-cell transcriptomics approach. Writing in Nature, the authors explain that they were able to map 1.3 million cells from 283 post-mortem brain…
Published on July 15, 2024
Dementia is an early sign of Alzheimer’s disease, but not all patients with it will go on to develop the progressive brain disorder for which there is no cure. Early detection, however, allows for the treatment of symptoms and the building support and medical care teams. Now, a team of…